Journal article
Candidaemia with uncommon Candida species: Predisposing factors, outcome, antifungal susceptibility, and implications for management
SCA Chen, D Marriott, EG Playford, Q Nguyen, D Ellis, W Meyer, TC Sorrell, M Slavin, J McBride, C Coulter, J McCormack, K Walmsley, D Looke, B Johnson, G Nimmo, G Playford, D Drummond, R Forgan Smith, E Preston, A Allworth Show all
Clinical Microbiology and Infection | ELSEVIER SCI LTD | Published : 2009
Abstract
The risk factors for and clinical features of bloodstream infection with uncommon Candida spp. (species other than C. albicans, C. glabrata, C. parapsilosis, C. tropicals and C. krusei) are incompletely defined. To identify clinical variables associated with these species that might guide management, 57 cases of candidaemia resulting from uncommon Candida spp. were analysed in comparison with 517 episodes of Candida albicans candidaemia (2001-2004). Infection with uncommon Candida spp. (5.3% of candidaemia cases), as compared with C. albicans candidaemia, was significantly more likely to be outpatient-acquired than inpatient-acquired (15 of 57 vs. 65 of 517 episodes, p0.01). Prior exposure t..
View full abstractGrants
Funding Acknowledgements
The study was supported by an educational grant from Pfizer Inc. M. Slavin, D. Marriott, D. Ellis, G. Playford and T. Sorrell are, or have been, on antifungal advisory boards of Gilead Sciences, Pfizer Australia, and Merck Sharp and Dohme, Australia; M. Slavin, D. Ellis, G. Playford and T. Sorrell are on the antifungal advisory board of Schering Plough; M. Slavin is on the antifungal advisory board of Bristol- Myers Squibb; T. Sorrell is on the advisory board of Pfizer Global; and S. Chen is on the antifungal advisory board of Gilead Sciences and Pfizer Australia. G. Playford and T. Sorrell have received financial support for research from Pfizer Australia and Merck Sharp and Dohme.